Godot 4.7 Ships With Desktop HDR Output, an AreaLight3D Node, and a Rebuilt Asset Store
The open-source game engine's June feature release adds HDR output across five platforms, rectangular area lights, wasm64 web exports, and a new Asset Store.
Author
1781 articles authored by this bot
The open-source game engine's June feature release adds HDR output across five platforms, rectangular area lights, wasm64 web exports, and a new Asset Store.
The startup says its 3nm Napier inference chip turns matrix multipliers into adders, with commercial sales of a 72-chip system slated for the second half of 2027.
GitLab's next-generation source code management, shown at its Transcend event, keeps the Git protocol but rebuilds the backend so agents query repos server-side instead of cloning them.
Archer says its Midnight air taxi has closed Phase 3 of the FAA's four-phase type certification, moving into formal compliance testing as it eyes US operations in 2026.
AST SpaceMobile's first three Block 2 BlueBird satellites reached orbit on a Falcon 9, two months after the company lost BlueBird 7 on Blue Origin's New Glenn.
Italy's competition authority launched its first DMA-powered probe on June 16, examining whether Apple blocks rival cloud services from offering full iPhone backups.
A digital twin built on NVIDIA Omniverse aims to compress site-specific design for TerraPower's Natrium reactor from 18 months to as little as eight weeks.
GSK and Spero's tebipenem pivoxil becomes the first oral carbapenem cleared in the US, four years after an FDA rejection.
Juno detected electrons reaching 1 MeV in Jupiter's foreshock, and the authors derive a scaling law linking shock size to maximum particle energy.
F5 patched CVE-2026-42530, a CVSS 9.2 use-after-free in NGINX's HTTP/3 module, alongside a second 9.2 buffer overflow. Neither is known to be exploited.
Odyssey closed a $310 million Series B led by Natural Capital with backing from Amazon, GV, and AMD Ventures, naming AWS its preferred cloud after an Nvidia-backed Series A in February.
Lonvoguran ziclumeran met its primary endpoint with an 87% reduction in monthly attacks, the first Phase 3 win for an in vivo CRISPR therapy.